Loading
A phase 2 trial of FOLFIRI, Bevacizumab, FOLFOX in colorectal cancer, run by Cardiff Oncology, active and no longer recruiting.
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation is a phase 2 interventional study registered as NCT06106308 by Cardiff Oncology, with 110 participants enrolled, started 2024-02-27 and due to reach its primary completion in 2026-11. Interventions recorded: Onvansertib, FOLFIRI, Bevacizumab, FOLFOX. Conditions listed: Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation. No results are recorded here; the registry entry is the source.
Shares Cardiff Oncology, Onvansertib.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Bevacizumab, Anti-angiogenic therapy.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Bevacizumab, Anti-angiogenic therapy.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), FOLFOX (5-FU, leucovorin, oxaliplatin), Bevacizumab, Anti-angiogenic therapy.